U.S. markets close in 4 hours 10 minutes
  • S&P 500

    3,782.86
    -66.76 (-1.73%)
     
  • Dow 30

    30,552.65
    -384.39 (-1.24%)
     
  • Nasdaq

    13,417.72
    -208.34 (-1.53%)
     
  • Russell 2000

    2,133.80
    -16.05 (-0.75%)
     
  • Crude Oil

    53.14
    +0.53 (+1.01%)
     
  • Gold

    1,846.40
    -4.50 (-0.24%)
     
  • Silver

    25.33
    -0.21 (-0.81%)
     
  • EUR/USD

    1.2109
    -0.0059 (-0.48%)
     
  • 10-Yr Bond

    1.0110
    -0.0290 (-2.79%)
     
  • GBP/USD

    1.3700
    -0.0032 (-0.23%)
     
  • USD/JPY

    104.0500
    +0.4230 (+0.41%)
     
  • BTC-USD

    30,748.75
    -1,084.15 (-3.41%)
     
  • CMC Crypto 200

    621.26
    -18.66 (-2.92%)
     
  • FTSE 100

    6,571.27
    -82.74 (-1.24%)
     
  • Nikkei 225

    28,635.21
    +89.03 (+0.31%)
     

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Could Be 41% Below Their Intrinsic Value Estimate

Simply Wall St
·6 min read

How far off is Intellia Therapeutics, Inc. (NASDAQ:NTLA) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting them to today's value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

View our latest analysis for Intellia Therapeutics

Step by step through the calculation

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

10-year free cash flow (FCF) estimate

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

-US$185.2m

-US$190.2m

-US$187.3m

-US$186.5m

US$190.5m

US$272.4m

US$356.0m

US$434.8m

US$504.7m

US$564.6m

Growth Rate Estimate Source

Analyst x4

Analyst x4

Analyst x2

Analyst x2

Analyst x2

Est @ 43%

Est @ 30.71%

Est @ 22.11%

Est @ 16.09%

Est @ 11.87%

Present Value ($, Millions) Discounted @ 7.4%

-US$172

-US$165

-US$151

-US$140

US$133

US$178

US$216

US$246

US$266

US$277

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$686m

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.0%. We discount the terminal cash flows to today's value at a cost of equity of 7.4%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$565m× (1 + 2.0%) ÷ (7.4%– 2.0%) = US$11b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$11b÷ ( 1 + 7.4%)10= US$5.3b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$6.0b. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of US$54.4, the company appears quite good value at a 41% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

dcf
dcf

The assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Intellia Therapeutics as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.4%, which is based on a levered beta of 1.024. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Looking Ahead:

Whilst important, the DCF calculation shouldn't be the only metric you look at when researching a company. DCF models are not the be-all and end-all of investment valuation. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Can we work out why the company is trading at a discount to intrinsic value? For Intellia Therapeutics, there are three relevant elements you should assess:

  1. Risks: To that end, you should be aware of the 3 warning signs we've spotted with Intellia Therapeutics .

  2. Future Earnings: How does NTLA's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.